Navigation Links
Takeda and Zinfandel Pharmaceuticals Initiate Phase 3 TOMMORROW Trial of AD-4833 for the Delay of Onset of Mild Cognitive Impairment Due to Alzheimer's Disease in Subjects Selected Using a Genetic-Based Biomarker Risk Assignment Algorithm
Date:8/26/2013

OSAKA, Japan and DURHAM, N.C., Aug. 26, 2013 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") and its partner, Zinfandel Pharmaceuticals, Inc. ("Zinfandel"), today announced the initiation of TOMMORROW, a global Phase 3 clinical trial investigating a genetic-based biomarker risk assignment algorithm (risk assignment algorithm) to predict risk of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) within a five year period and to evaluate the efficacy of the investigational low dose pioglitazone (designated AD-4833 for this use) in delaying the onset of MCI due to AD in cognitively normal individuals at high risk as determined by the risk assignment algorithm.

The risk assignment algorithm is comprised of apolipoprotein E (APOE) and TOMM40 genotypes and age. Age and APOE genotype have previously been shown to indicate elevated risk of AD. The addition of TOMM40 is hypothesized to further refine the risk determination.

"To date, there have been a number of avenues investigated with the goal of altering the course of Alzheimer's disease but results have been unsuccessful," said Allen Roses, M.D., Chief Executive Officer, Zinfandel. "This is why the TOMMORROW trial is important. The potential to identify an individual's risk for developing MCI due to AD warrants further investigation."

AD is a devastating disease and diagnoses are increasing as the world's population ages. Currently 35.6 million people worldwide are living with some form of dementia. Studies show that individuals with MCI are at an increased risk of developing AD or another dementia with conversion rates of approximately 15 percent per year.

"AD-4833 is a member of a class of drugs known as PPAR (peroxisome proliferator-activated receptor)-gamma agonists which available data show may have a beneficial role in delaying symptoms of MCI due to AD," noted '/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Takeda Launches New Subsidiary in Peru
2. Data Published in the New England Journal of Medicine for Vedolizumab, an Investigational New Drug from Takeda for Moderately to Severely Active Ulcerative Colitis and Crohns Disease
3. Among New Agents Entering the Unipolar Depression Market Over the Next Decade, Lundbeck/Takeda Pharmaceuticals Brintellix Has Blockbuster Potential
4. Takeda Submits Biologics License Application for a New Investigational Drug Vedolizumab, in Moderately to Severely Active Crohns Disease and Ulcerative Colitis in the United States
5. Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States
6. AGA Research Foundation Announces Endowment Gift from Takeda Pharmaceuticals U.S.A., Inc. to Support Gastroenterology Research
7. Takeda to Acquire Inviragen, Inc.
8. Takeda Responds to Verdict in Diabetes Drug Case
9. Takeda Launches New Subsidiary in Ecuador
10. Takeda lanza nueva subsidiaria en Ecuador
11. Scripps Research Institute and Takeda Pharmaceuticals Announce Expanded Research Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... PLEASANTON, Calif. , Nov. 26, 2014  Thoratec ... in device-based mechanical circulatory support therapies to save, support ... participating in two upcoming investor conferences. On ... 26 th Annual Piper Jaffray Healthcare Conference.  ... will provide an update on the company beginning at ...
(Date:11/26/2014)... -- Perrigo Company plc ("Perrigo") (NYSE: PRGO ; ... Products®," today announced the closing of Perrigo,s previously announced ... ordinary shares at a public offering price of $152.00 ... to purchase up to an additional 888,157 ordinary shares ... as representatives of the several underwriters. ...
(Date:11/26/2014)... , Nov. 26, 2014 Lexicon Pharmaceuticals, ... the completion of previously announced concurrent financing transactions ... fees and estimated offering expenses, Lexicon anticipates net ...  The transactions consisted of: , a ... pursuant to a registration statement that has been ...
Breaking Medicine Technology:Thoratec Announces Presentations At Investor Conferences For December 2014 2Perrigo Company plc Announces The Closing Of Its Registered Public Offering Of Ordinary Shares 2Perrigo Company plc Announces The Closing Of Its Registered Public Offering Of Ordinary Shares 3Perrigo Company plc Announces The Closing Of Its Registered Public Offering Of Ordinary Shares 4Lexicon Announces Completion Of $280 Million In Financing Transactions 2Lexicon Announces Completion Of $280 Million In Financing Transactions 3
... announced that it has filed a lawsuit in the Netherlands ... Labem, Czech Republic, where Dr. Cervinka is head of the ... conducted at the Masaryk Hospital, in which Dr. Cervinka was ... stent with a bare metal stent for treatment of a ...
... CSL Behring today announced the development ... absorption, distribution, metabolism, and elimination of subcutaneous (SC) immunoglobulin ... high degree of accuracy and precision. The new PK ... by which SC IgG is transported after it is ...
Cached Medicine Technology:OrbusNeich Files Lawsuit Against Dr. Pavel Cervinka for Defamation 2OrbusNeich Files Lawsuit Against Dr. Pavel Cervinka for Defamation 3New Model Provides Insights Into Intravenous and Subcutaneous Immunoglobulin Pharmacokinetics in Patients With Primary Immunodeficiencies 2New Model Provides Insights Into Intravenous and Subcutaneous Immunoglobulin Pharmacokinetics in Patients With Primary Immunodeficiencies 3New Model Provides Insights Into Intravenous and Subcutaneous Immunoglobulin Pharmacokinetics in Patients With Primary Immunodeficiencies 4New Model Provides Insights Into Intravenous and Subcutaneous Immunoglobulin Pharmacokinetics in Patients With Primary Immunodeficiencies 5New Model Provides Insights Into Intravenous and Subcutaneous Immunoglobulin Pharmacokinetics in Patients With Primary Immunodeficiencies 6
(Date:11/28/2014)... November 29, 2014 TideStore.com , has ... new dresses, shoes and other fashion items recently. Its 2014 ... site. , The special offer is valid during Nov. ... tops, stylish women outwears, charming dresses, shining prom shoes, essential ... leading online store offering many trendy clothes and fashion accessories. ...
(Date:11/28/2014)... 2014 The report “Poxvirus Infections ... the therapeutic development for Poxvirus Infections, complete with ... drug target, mechanism of action (MoA), route of ... updates, and featured news and press releases. It ... development for Poxvirus Infections and special features on ...
(Date:11/28/2014)... sells cheap tall cocktail dresses worldwide and ... there is a new collection of tall cocktail dresses ... at very low prices. It is really worthy to ... by UWDress.com , UWDress.com is one of the most ... has the power to ensure customer satisfaction. Now, the ...
(Date:11/28/2014)... 29, 2014 Angelweddingdress.com, a world-famous ... collection of Blue Color Styles of ... up to 80% off and free shipping on ... discounted blue bridesmaid dresses for less at the ... Angelweddingdress.com is famous as a reliable dress supplier ...
(Date:11/28/2014)... New York, NY (PRWEB) November 28, 2014 ... ground-breaking physical therapy techniques such as Dynamic Neuromuscular ... therapy, and gait/motion analysis. After moving to upgraded ... sports and running clinic. Now, owner Dr. Lev ... movement performance and injury prevention lab in the ...
Breaking Medicine News(10 mins):Health News:2014 Special Monday Sales from TideStore.com 2Health News:Poxvirus Infections and Vestibular Diseases Pipeline Market Drugs and Companies Review H2 2014 2Health News:Poxvirus Infections and Vestibular Diseases Pipeline Market Drugs and Companies Review H2 2014 3Health News:Poxvirus Infections and Vestibular Diseases Pipeline Market Drugs and Companies Review H2 2014 4Health News:Graceful Tall Cocktail Dresses With New Features Just Added To UWDress.com 2Health News:Blue Color Styles of Bridesmaid Dresses from AngelWeddingDress.com are Available Now With Big Discounts 2Health News:New York Dynamic Neuromuscular Rehabilitation Opens Nation's Most Advanced Movement Performance and Injury Prevention Lab 2Health News:New York Dynamic Neuromuscular Rehabilitation Opens Nation's Most Advanced Movement Performance and Injury Prevention Lab 3
... ANN ARBOR, Mich. -- Only about one in five young ... the 2009-2010 swine flu epidemic, according to a University of ... X. But about 65 percent were at least moderately ... were following the issue very or moderately closely. Using ...
... Marriage offers few well-being advantages compared to living together, a ... benefits of marriage diminish over time, while unmarried couples who ... data from 2,737 single men and women who took part ... those people, 896 married or moved in with a partner ...
... Reporter , MONDAY, Jan. 23 (HealthDay News) -- Shedding some light ... finds that parts of your immune system ramp up when you ... this effect of stress may make you sick, but the activated ... body -- have been linked to conditions such as diabetes and ...
... MONDAY, Jan. 23 (HealthDay News) -- Although many people believe ... the opposite may be true with traumatic brain injuries. ... injury in children as young as 2 years, and found ... for some time. However, the researchers also found that recovery ...
... more than 40 years, scientists and physicians have thought eating ... disease of the large intestine in which pouches develop in ... people reveals the opposite may be true. The study, ... Chapel Hill School of Medicine , found that consuming a ...
... A new study published online today in the ... finds hospitals participating in a regional collaborative of the ... (ACS NSQIP), achieved substantial improvements in surgical outcomes, such ... surgical site infections. The collaborative also saved $2,197,543 per ...
Cached Medicine News:Health News:Generation X: How young adults deal with influenza 2Health News:Living Together May Be Mentally Healthier Than Marriage: Study 2Health News:Study Shows How Stress Triggers Immune System 2Health News:Study Shows How Stress Triggers Immune System 3Health News:Severe Brain Injury When Young May Have Long-Term Effects 2Health News:Severe Brain Injury When Young May Have Long-Term Effects 3Health News:Severe Brain Injury When Young May Have Long-Term Effects 4Health News:Diets high in fiber won't protect against diverticulosis 2Health News:Regional surgical quality collaborative significantly improves surgical outcomes and reduces cost 2Health News:Regional surgical quality collaborative significantly improves surgical outcomes and reduces cost 3
... The Series I Instrument program offers state-of-the-art ... profile, while maintaining strength and durability. Low ... in tight joint spaces. Series I instruments ... tip style, size and angle required for ...
... facilitates fast and effective resection of meniscal ... meniscal rim. The flat, crescent-shaped tip has ... the tightest joint spaces. Made in the ... of engineering experience in arthroscopy hand instrument ...
... facilitates fast and effective resection of meniscal ... meniscal rim. The flat, crescent-shaped tip has ... the tightest joint spaces. Made in the ... of engineering experience in arthroscopy hand instrument ...
... The WideBiter Punch series facilitates fast and ... a smooth, anatomically shaped meniscal rim. The ... profile to access even the tightest joint ... California, Inc., 20 years of engineering experience ...
Medicine Products: